SPIA
DMAC icon

Steward Partners Investment Advisory’s DiaMedica Therapeutics DMAC Stock Holding History

Steward Partners Investment Advisory’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.6K Buy
+1,500
New +$9.22K ﹤0.01% 3711

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Steward Partners Investment Advisory's DMAC Position: Q2 2026 in Review

Steward Partners Investment Advisory opened a new position in DiaMedica Therapeutics (DMAC) in Q2 2026: 1,500 shares worth $10.6K. The stake represents ﹤0.01% of the portfolio and ranks #3711 among its holdings.

70 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • Steward Partners Investment Advisory held 1,500 shares of DiaMedica Therapeutics worth $10.6K as of Q2 2026.
  • DiaMedica Therapeutics was a new Steward Partners Investment Advisory position in Q2 2026.
  • DiaMedica Therapeutics made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #3711 holding.
  • 70 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.